Teleflex Inc. (TFX) saw its shares plummet 5.01% in Friday's trading session, following the company's disappointing fourth-quarter earnings report and weak 2025 guidance. The medical device maker's revenue for Q4 2024 missed analyst expectations, and its projected 2025 revenue growth outlook of just 1-2% year-over-year, excluding foreign exchange impacts, fell short of consensus estimates.

Adding to investor concerns, Teleflex announced plans to separate its Urology, Acute Care, and OEM segments into a publicly traded company by mid-2026. While the strategic move may deliver long-term benefits, analysts raised questions about the current state of the business and the uncertainties surrounding the planned spinoff.

In response to the challenging growth outlook and separation plans, several Wall Street analysts downgraded Teleflex and lowered their price targets on the stock. Firms like RBC Capital, Raymond James, and Piper Sandler cited concerns over slowing fundamentals, particularly in the company's Urolift business, and the disruption that typically accompanies such corporate actions.